Prime Medicine, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; it does not provide separate fourth-quarter results. Prime Medicine is a preclinical biotechnology company developing Prime Editing genetic medicines. It reported no product revenue and had not begun clinical development of a product candidate.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $147.9 million | $86.7 million |
| General and administrative expense | $43.4 million | $29.8 million |
| Total operating expenses | $204.8 million | $116.5 million |
| Net loss | $198.1 million | $121.8 million |
| Net loss per share, basic and diluted | $2.18 | $4.19 |
| Net cash used in operating activities | $165.4 million | $131.8 million |
- At December 31, 2023, cash, cash equivalents, short-term investments and the Beam-related-party investment totaled $121.7 million, excluding $13.5 million of restricted cash. Total current assets were $143.0 million and current liabilities were $56.4 million.
- Cash, cash equivalents and restricted cash declined by $146.0 million during 2023. Investing activities provided $18.7 million, primarily reflecting net maturities of investments; financing activities provided $0.7 million.
- The filing reports no borrowings. Lease obligations include $14.6 million of remaining payments on commenced leases and an approximately $208.7 million commitment over the initial 10-year term of the 60 First Street lease, which had not commenced at year-end.
- Management estimated that year-end funds, together with net proceeds from the February 2024 offering, would fund operations and capital expenditures into the third quarter of 2025. Management also states that additional financing will be needed to support continuing operations and growth.
Material changes and notable items
- Net loss increased by $76.3 million year over year. R&D expense rose by $61.2 million, primarily due to expanded research activity, higher lab-supply and personnel costs, and facility expansion. G&A expense increased by $13.6 million.
- Operating cash use increased by $33.6 million from 2022. Accumulated deficit reached $491.3 million, and stockholders’ equity declined to $133.1 million from $316.3 million.
- A $13.5 million Myeloid settlement charge was recorded in 2023. In January 2024, the parties settled their arbitration disputes, with Prime Medicine agreeing to pay that amount and the parties releasing related claims.
- In February 2024, after year-end, the company raised approximately $150.9 million net through a public offering of common shares and pre-funded warrants. The offering increased potential share dilution. The company also had an unused at-the-market program permitting up to $300 million in sales as of year-end.
- Interest and other income was $8.8 million in 2023, compared with $1.9 million in 2022; the change in fair value of the Beam investment generated a $2.4 million loss in 2023 versus an $8.1 million loss in 2022.
Business outlook, commentary and risks
- PM359, for p47phox chronic granulomatous disease, is the company’s lead candidate. Management planned to submit an IND and/or CTA in the first half of 2024; the filing describes IND-enabling work, not a clinical-stage program. FDA rare pediatric disease designation was received in August 2023 and orphan drug designation in January 2024.
- Other programs—including Wilson’s disease, glycogen storage disease 1b, cystic fibrosis, RHO-related retinitis pigmentosa, Friedreich’s ataxia and myotonic dystrophy type 1—remain in preclinical development. Reported editing and safety findings are preclinical and do not establish clinical benefit or safety.
- In January 2024, the Cystic Fibrosis Foundation agreed to provide up to $15 million to support cystic fibrosis development; the foundation may receive royalties on net sales.
- The company reported 2023 preclinical proof-of-concept findings, including Prime Editing in non-human primates for GSD1b, and described PASSIGE CAR-T work. These programs face substantial development, delivery, manufacturing and regulatory uncertainty.
- Key risks include continued losses and need for capital; the unvalidated clinical potential of Prime Editing; off-target or delayed adverse effects from permanent editing; regulatory uncertainty; dependence on third-party manufacturers and research partners; competition; and the scope, enforceability and licensing terms of intellectual property. The company also disclosed Broad Institute license conditions and potential march-in rights.
- The independent auditor issued an unqualified opinion on the financial statements and emphasized that additional financing will be required. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not attest to internal-control effectiveness because of the company’s emerging-growth-company exemption.
Most important facts for investors to verify
- Whether PM359’s IND/CTA was submitted on the stated schedule, and any FDA or other regulatory feedback, clinical holds or changes to trial plans.
- Current cash and investment balances, actual cash burn, use of the February 2024 proceeds, and any subsequent financing or revised runway estimate.
- The full dilution impact of the February offering, pre-funded warrants, stock compensation and any ATM sales.
- Progress and reproducibility of preclinical results, especially editing specificity, delivery, durability, safety and evidence that biomarkers could translate into patient benefit.
- Costs and occupancy plans for the 60 First Street lease, including the long-term commitment, alongside other lease liabilities.
- Any further Myeloid settlement developments, collaboration milestones or changes in material license rights and obligations.